BRAIN and NERVE Shinkei Kenkyu no Shinpo Volume 61, Issue 8 (August 2009)

Molecular Target Drug Development for Curing Multiple Sclerosis Takashi Yamamura 1 1Department of Immunology,National Institute of Neuroscience,National Center of Neurology and Psychiatry Keyword: multiple sclerosis (MS) , humanized antibody , integrin , sphingosine 1-phosphate (S1P) , clinical trial pp.923-928
Published Date 2009/8/1
  • Abstract
  • Look Inside
  • Reference


 Multiple sclerosis (MS) is a chronic central nervous system disease in which autoimmune mechanisms are operative. Although it appears that the prognosis of MS has been significantly improved after interferon-β and glatiramer acetate were introduced in clinic,many patients are still refractory to available medications,and the necessity to develop new treatment options is obvious. Current trend in the drug discovery is to find or make a drug whose molecular target is clearly identified. This is also the case for the development of drugs for MS. Here I review current status in the development of so-called "molecular target drugs" for MS. In general,effects of such drugs well fit to the expected mechanism of action. Although concerns about opportunistic infections including JC virus-mediated progressive multi-focal leukoencephalopathy (PML) have not been dissolved,better clinical and laboratory monitoring of the immune system of the patients may help minimize potential side effects of these drugs.

Copyright © 2009, Igaku-Shoin Ltd. All rights reserved.


BRAIN and NERVE-神経研究の進歩
61巻8号 (2009年8月)
電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院